

November 14, 2022
HIROTSU BIO SCIENCE INC.

HIROTSU BIO SCIENCE Joins World Economic Forum Global Innovators Community

— President CEO, Dr. Hirotsu, will attend the Annual Meeting in 2023 —

HIROTSU BIO SCIENCE INC. (Representative: Takaaki Hirotsu, hereafter referred to as HIROTSU) has joined the Global Innovators Community of World Economic Forum since November 1 of this year. This community brings together the world's most promising start-ups and scale-ups that are at the forefront of technological and business model innovation. As a leading company contributing to health and medicine with cutting-edge and proprietary biotechnologies, HIROTSU is committed to realizing a better future.



HIROTSU is pleased to announce our participation in the Global Innovators Community of the World Economic Forum. This is a reflection of the company's R&D and technological capabilities in the development and provision of N-NOSE[®] nematode cancer test, as well as its new concept of using the sense of smell of living organisms as a sensor and its novel business model of primary screening for cancer, which HIROTSU believes will contribute to innovation in solving global issues.

HIROTSU is proud to be one of the leaders in creating a better world, and will continue to expand their business without slowing down in their research and development.

In January 2023, President CEO, Dr. Takaaki Hirotsu, will attend the World Economic Forum Annual Meeting to be held in Davos, Switzerland.

【Reference】

■What is the World Economic Forum?

The World Economic Forum is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business, cultural and other leaders of society to shape global, regional and industry agendas. It was established in 1971 as a not-for-profit foundation and is headquartered in Geneva, Switzerland. It is independent, impartial and not tied to any special interests. The Forum strives in all its efforts to demonstrate entrepreneurship in the global public interest while upholding the highest standards of governance. Moral and intellectual integrity is at the heart of everything it does.

■About N-NOSE nematode cancer screening

N-NOSE is the world's first primary cancer screening test that utilizes "nematodes," microorganisms that are highly sensitive to the odor of cancer in human urine. Clinical research has shown that nematodes even respond to early-stage cancer (stages 0 and I), which is difficult to detect with conventional screening methods.

The fact that cancer risk can be assessed in one test, regardless of the location in the body,* is another strength that sets N-NOSE apart from other tests.

* Types of cancer that nematodes are known to respond to: stomach, colorectal, lung, breast, pancreatic, liver, prostate, uterine, esophageal, gall bladder, bile duct, kidney, bladder, ovarian, oral/pharyngeal—15 types of cancer (as of September 2019)

【HIROTSU BIO SCIENCE INC.】

Address: New Otani Garden Court 4-1 Kioi-cyo, Chiyoda-ku, Tokyo

President and CEO: Takaaki Hirotsu

Founded: August 2007

Business: Research, development, and sale of a cancer screening test that utilizes the olfactory sensory functions of nematodes

URL: <https://hbio.jp/en/>